LOS ANGELES, Aug. 16, 2022 (GLOBE NEWSWIRE) — via InvestorWire – IBN, a multifaceted financial news and publishing company for public and private entities, today announced that NFL Hall of Famer Brett Favre and Dr. Jacob VanLandingham, Head of Drug Development for medical technology company Odyssey Health Inc. (OTC: ODYY), was recently featured in Dr. Finance Live, a podcast series focused on changing the way you think about economics and finance.
The broadcast, presented by best-selling author and entrepreneur Dr. Anthony M. Criniti IV (aka “Dr. Finance®”), is available for on-demand viewing at Dr. Finance Live.
During the interview, Favre discussed how his passion for discovering a treatment for concussion led him to his current position as a member of Odyssey Health’s sports advisory board.
“When I retired for good in 2011 after 20 years, I had something to lean on, obviously my family…but I don’t want to own businesses and manage 500 employees. That’s not my cup of tea,” Favre said. “Really what I’m most passionate about right now is [uncovering a concussion treatment] … The last play of my career was a major concussion. I don’t want to act like I’m an expert on concussions, but I do know this: there’s never a good time to have a major concussion. What little we know about concussions compared to when I started playing in 1991 is that they are terrible, and the repercussions can range from death to all kinds of mental illness.”
“[Dr. VanLandingham] I came into my life through a chance meeting with a mutual friend, and that meeting basically led to where we are today,” Favre continued. “My role in [working with Odyssey Health] is to raise awareness and provide funding… Many doors have been closed in our face, but we continue to transport ourselves. This is really my passion, watching this dope. Plain and simple, there is no treatment for concussions and the NFL, as great as they are, puts their money and effort into prevention. It’s a good job, but you won’t stop it [all] concussions… We need something you can take right away that can counteract the effects of concussion. As much as [the NFL] has improved helmets and improved rules, concussions are still a serious issue in the game of football and, frankly, in the game of life.”
Dr. VanLandingham then provided an overview of Odyssey’s PRV-002, a new compound being evaluated in clinical trials for the treatment of concussion.
“[PRV-002] is a new neurosteroid that affects brain tissue. As a steroid, the drug will go directly into the traumatized brain cells and diffuse into them,” VanLandingham explained. “Steroids activate your DNA, which is in your nucleus. Specifically, our steroid activates DNA sequences that lead to the production of proteins that reduce swelling, inflammation and oxidative stress. It’s a drug that we know can get to the brain that works like a cocktail of drugs… The drug is formulated as an aerosol-dried powder and put into an intranasal device. As a spray-dried powder, it is stable and therefore maintains its effectiveness at high temperatures. Whether you’re on the sidelines of a football field in Florida or on a military operation in Afghanistan, [PRV-002] it will be stable and effective.”
Throughout the interview, Favre and VanLandingham discussed Odyssey’s recent clinical development milestones and how they relate to the company’s ongoing efforts to address the critical unmet need for a concussion treatment option approved
More information by watching the full interview with Dr. Finance Live.
About Odyssey Health Inc.
Odyssey Health Inc. (OTC: ODYY) is a medical company focused on the area of medical solutions that can save lives. Odyssey’s corporate mission is to create, acquire and develop exceptional assets, intellectual property and technologies that deliver meaningful medical solutions. The Company focuses on areas that have an identified technological advantage, offer superior clinical utility and have a substantial market opportunity. For more information, visit the company’s website at www.OdysseyHealthInc.com
About the IBN
IBN consists of financial brands introduced to the investing public over more than 15 years. With IBN, we’ve built a collective audience of millions of social media followers. These distinctive investor brands aim to meet the unique needs of a growing customer-partner base. IBN will continue to expand our brand network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diverse client list.
Through NetworkNewsWire (“NNW”) and its Investor Brand Platform, IBN offers: (1) access to a network of wire solutions through InvestorWire to reach all target markets, industries and demographics in the manner as effective as possible; (2) syndication of articles and editorials to more than 5,000 media outlets; (3) Improving the press release to ensure maximum impact; (4) large-scale distribution to a growing social media audience; (5) a full range of corporate communications solutions; and (6) total news coverage solutions.
For more information, visit
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions about future events or the company’s future performance. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating these statements, prospective investors should carefully review various risks and uncertainties identified in this release and matters set forth in the company’s filings with the SEC. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
Los Angeles, California